For example, we have recently shown that in a subpopulation of HNSCC patients with FAT1 mutations, YAP1, and bromodomain-containing protein 4 (BRD4) can be therapeutically targeted with BET bromodomain inhibitors [132]. Here, BRD4 is linked to head and neck squamous cell carcinoma.